Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Galli

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Lung Cancer|August 1, 2020
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS StudyDiego Cortinovis, Federica Grosso, Luciano Carlucci, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Journal of the American Academy of Dermatology|November 17, 2016
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 casesMario Mandalà, Francesca Galli, Laura Cattaneo, et al.
British Journal of Cancer|July 31, 2018
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcomaAngiolo Gadducci, Federica Grosso, Giovanni Scambia, et al.
International Journal of Cancer|September 3, 2022
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infectionNicla La Verde, Agostino Riva, Maria Silvia Cona, et al.
Cancer Medicine|April 28, 2023
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patientsMaria Silvia Cona, Agostino Riva, Davide Dalu, et al.
British Journal of Cancer|September 21, 2019
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancerNicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2020
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)Mario Mandalà, Francesca Galli, Roberto Patuzzo, et al.
The Oncologist|January 17, 2020
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup AnalysisGerardo Rosati, Fabio Galli, Maurizio Cantore, et al.
Clinical Colorectal Cancer|March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA TrialDebora Basile, Gerardo Rosati, Francesca Bergamo, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Lung Cancer|August 1, 2020
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS StudyDiego Cortinovis, Federica Grosso, Luciano Carlucci, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Journal of the American Academy of Dermatology|November 17, 2016
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 casesMario Mandalà, Francesca Galli, Laura Cattaneo, et al.
British Journal of Cancer|July 31, 2018
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcomaAngiolo Gadducci, Federica Grosso, Giovanni Scambia, et al.
International Journal of Cancer|September 3, 2022
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infectionNicla La Verde, Agostino Riva, Maria Silvia Cona, et al.
Cancer Medicine|April 28, 2023
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patientsMaria Silvia Cona, Agostino Riva, Davide Dalu, et al.
British Journal of Cancer|September 21, 2019
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancerNicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2020
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)Mario Mandalà, Francesca Galli, Roberto Patuzzo, et al.
The Oncologist|January 17, 2020
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup AnalysisGerardo Rosati, Fabio Galli, Maurizio Cantore, et al.
Clinical Colorectal Cancer|March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA TrialDebora Basile, Gerardo Rosati, Francesca Bergamo, et al.
Pageof 6